Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | FGF1 | P05230 | 1/20 | 0.31 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.30 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.30 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12360822 | 1.00 | LGALS8 (0.36) | LGALS8OGAFGF1SSTR5SSTR1 | |
| SCHEMBL13513423 | 1.00 | LGALS8 (0.36) | LGALS8OGAFGF1SSTR5SSTR1 | |
| SCHEMBL27393414 | 1.00 | LGALS8 (0.36) | LGALS8OGAFGF1SSTR5SSTR1 | |
| SCHEMBL12376380 | 1.00 | LGALS8 (0.36) | LGALS8OGAFGF1SSTR5SSTR1 | |
| SCHEMBL13513424 | 0.87 | — | — | |
| SCHEMBL12360821 | 0.87 | — | — | |
| SCHEMBL22699770 | 0.85 | OGA (0.32) | LGALS8OGA | |
| SCHEMBL14537231 | 0.85 | FGF1 (0.31) | LGALS8OGAFGF1 | |
| SCHEMBL24931089 | 0.84 | OGA (0.34) | LGALS8OGASSTR5SSTR1SSTR2 | |
| SCHEMBL15691431 | 0.82 | LGALS8 (0.50) | LGALS8OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801311-B2 | Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides | GENZYME CORPORATION (US) | 2023-10-31 | — | — | US | disclosed |
| US-10682423-B2 | Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides | GENZYME CORPORATION (US) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682423-B2 | Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides | GYS1, PYGM, TNNC1 | LGALS8 1399/4885OGA 94/4885FGF1 4720/4885 |
| US-11801311-B2 | Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides | GYS1, PYGM, TNNC1 | LGALS8 1399/4885OGA 94/4885FGF1 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.